This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies
| 4 min read
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
| 1 min read
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
| 5 min read
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
| 2 min read
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
| 4 min read
The treatment has the potential to prevent Aspergillus fungal infections in people who have had a lung transplant.
| 4 min read
Foundation to fund up to $110 million for collaboration to accelerate the development of genetic therapies for CF
| 4 min read
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
| 3 min read